Below is a selection of educational resources, including Immunexpress sponsored webinar presentations and podcasts and sepsis information from authoritative advocacy groups and international health agencies, such as the Centers for Disease Control and Prevention (CDC) and National Institutes Health (NIH) and the open access journal JAMA Network.
In this presentation entitled, “A host response test to address the challenges of early sepsis diagnosis,” Dr. Robert Balk, Professor in the Department of Internal Medicine at Rush Medical College and Dr. Roy Davis, Chief Medical Officer of Immunexpress, discussed sepsis and the current challenges of sepsis diagnosis. Dr. Balk explained the burden of sepsis, the challenge of diagnosing sepsis, the benefits of rapid diagnosis and shared performance data from the clinical validation study of SeptiCyte RAPID, which recently received FDA clearance. Dr. Davis explained the challenges in diagnostic differentiation and the risk of under- or over-treating patients suspected of sepsis. He presented two case studies and reviewed how SeptiCyte® RAPID aligns with the new 2021 guidelines for sepsis clinical management from the Surviving Sepsis Campaign.
Roy Davis, M.D., Ph.D., MHA, Chief Medical Officer of Immunexpress, discussed differentiating sepsis from non-infectious systemic inflammation using FDA-cleared SeptiCyte® RAPID, a one-hour gene expression assay, in this webinar hosted by Biocartis. In this webinar, Dr. Davis explained the challenges in this diagnostic differentiation and the risk of under- or over-treating patients suspected of sepsis. He reviewed the clinical validation data for SeptiCyte® RAPID and how this host response test could assist with diagnostic uncertainty and impact the early initiation of appropriate therapy and outcome. Additionally, Dr. Davis reviews how SeptiCyte® RAPID aligns with the new 2021 guidelines for sepsis clinical management from the Surviving Sepsis Campaign.
Roy Davis, M.D., Ph.D., MHA, Chief Medical Officer of Immunexpress, presented an educational webinar hosted by Biocartis focused on SeptiCyte® RAPID in COVID-19 patients suspected of sepsis. In this webinar, Dr. Davis discussed the similarities between bacterial sepsis and severe COVID-19 illness, reviewed the data supporting SeptiCyte® RAPID for risk stratification of COVID-19 patients suspected of sepsis including a comparison to other biomarkers, and presented case studies that illustrate how SeptiCyte® RAPID could address the challenge of triaging COVID-19 patients.
A Podcast on Differentiating between Sepsis and SIRS
In this podcast, Dr. Annette Esper, Assoc. Prof of Medicine at Emory University School of Medicine and Medical Director of step-down ICU at Grady Memorial Hospital, describes the challenges associated with differentiating between sepsis and infection negative systemic inflammation in sepsis patients with varying levels of clinical suspicion and probability. Furthermore, she addresses the dilemma of under or over-treating suspected sepsis patients in order to comply with CMS SEP-1 quality metrics and follow the new SSC clinical management guidelines for sepsis. She also outlines how the newly FDA-cleared SeptiCyte RAPID test, might assist with this diagnostic uncertainty and impact early appropriate therapy and outcomes in the ICU.
Dr. Roy Davis, an intensivist and quality program consultant, describes the current challenges associated with diagnosing sepsis and how they might be addressed by a recently FDA-cleared one-hour host response test. He will cover clinical validation of the test and how it might fit in the clinical workflow, aligning with the new SSC guidelines.
In this webinar, hosted by Biocartis, Dr. Roy Davis reviews SeptiCyte® technology and its clinical validation in peer-reviewed journals and a correlation study of FDA cleared SeptiCyte® LAB with the 2nd generation, SeptiCyte® RAPID, which runs on Idylla™, generating results in 1 hr. Additionally, he presents recent data for the performance of SeptiCyte® RAPID in various patient cohorts, including candidemia, immunocompromised, oncology and COVID-19
Dr. Roy Davis provides an overview of the current challenges of sepsis diagnosis and management, specifically related to early identification and appropriate intervention. He describes how the host immune response can be leveraged by including a gene expression assay as part of the Sepsis Clinical Toolset. The proposed role for this assay in the clinical workflow and sepsis program triage is covered along with its impact on diagnostic uncertainty.
A Podcast on Severe COVID-19 and Sepsis
Severe COVID-19 infection can be a form of viral sepsis with occasionally concomitant bacterial infection. Pamela M. Peeke MD, MPH, FACP, FACSM, is joined by Russell Miller, MD, MPH, FCCM, to discuss the definition of sepsis and overlap with case descriptions of patients with severe COVID-19, how experience with viral sepsis can be leveraged to diagnose and treat COVID-19 patients being admitted to ICU, and the need to be able to differentiate viral from bacterial sepsis to avoid over or under treatment. Dr. Miller is medical director of critical care at FirstHealth of the Carolinas in Pinehurst, North Carolina, USA.
A Podcast on Sepsis Quality Improvement Program Components
Effectively addressing bacterial, fungal and viral sepsis requires a collaborative approach, with early identification and intervention being central to improving outcomes. Yet several barriers remain to building an effective sepsis quality improvement program. Host Michael Smith, MD, along with Erkan Hassan, PharmD, FCCM, and Roy Davis, MD, PhD, MHA, explores the specific components of a sepsis improvement program that healthcare professionals and hospitals must consider. Dr. Hassan is a principal of Transformational Views Consulting Group and cofounder and chief clinical officer of Sepsis Program Optimization. Dr. Davis is chief medical officer of Immunexpress Inc.
This webinar, given by Dr. Roy Davis, Chief Medical Officer of Immunexpress, addresses the shortcomings of past and current sepsis clinical criteria in accurately capturing patients with critical illness due to infection. The current status of microbiologic methods and single peptide biomarker will be described. A novel approach utilizing the host gene response to infection, SeptiCyte®, will be presented.
Learn about SeptiCyte® RAPID, a host response test, with actionable results in approximately one hour, differentiating sepsis from systemic inflammatory response syndrome (SIRS) with high negative predictive value (NPV), thus expediting and improving patient management for critically ill patients being admitted to the ICU. Steven P. LaRosa, MD, will address the challenges of current sepsis diagnosis and a new alternative approach leveraging the host immune response while Russell R® Miller III, MD, will present highlights from the VENUS study, a clinical validation of SeptiCyte® LAB.